- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02575352
Calcium Phosphate Cement Registry (CPC Registry) (CPC)
Observational Prospective Multi-center International Study on the Use of Injectable Calcium Phosphate Cements for the Treatment of Bone Defects in Adults.
Study Overview
Status
Conditions
Detailed Description
The objective of this observational prospective study is to collect safety and performance data relating to the use of injectable Calcium Phosphate Cements "GRAFTYS®HBS/GRAFTYS®Quickset (or their private labels)" in routine clinical practice from various international hospitals. Therefore this observational study will allow to support data about risk management (established at the end of the product development); and to enhance the current clinical evaluation of products with new clinical data (for longer follow-up). The collected data of this observational study will be "non-identifying data". The patient must have signed a Written Consent Form (for data collection) prior to any data being entered into the electronic Case Report Form.
Patients will be followed as per local standard medical practices of the center for two years. Five follow-up visits/phone calls will be collected (at 3 months (+/-14 days), 6 months (+/- 14 days), 9 months (+/-21 days), 12 months (+/- 30 days) and 24 months (+/-60 days)). Each visit/phone call includes the collection of Adverse Events, the measurement of health status (quality of life and functional scores) and the X-ray scoring (if X-ray imaging is available). No additional exams (other than the routine clinical practice) are requested. The surgeons have to follow their usual practices (e.g. X-Rays have to be performed only if they are scheduled in the routine clinical practice).
All Adverse Events will be collected and monitored at each follow-up visit or follow-up phone call. All Serious Adverse Events must be described via a Serious Adverse Event form in e-CRF and all Adverse Device Effects must be described via a "Product Complaint Form" in e-CRF.
Descriptive analyses will be performed in order to describe: nature of adverse events, their distribution and frequency. Moreover, all factors which may appear predictive for the rate of adverse events will be analyzed (age, sex, amount of CPC injected, delivery system used, diabetes history, smoking habits, alcohol consumption, concomitant treatments/diseases…). For all time-dependent events, life-tables will be able to calculate using the Kaplan Meier estimate method, for a period starting on the date of the procedure up to and including the 24-months follow-up visit.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Mehan ALTAIFI
- Phone Number: +33(0) 442 603 000
- Email: mehan.altaifi@graftys.fr
Study Contact Backup
- Name: Nathalie BAUDRY
- Phone Number: +33(0) 442 603 009
- Email: nathalie.baudry@graftys.fr
Study Locations
-
-
-
Marseille, France, 13385
- Recruiting
- Hôpital La Timone
-
Contact:
- Sébastien PARRATTE, MD, Prof.
-
Principal Investigator:
- Sébastien PARRATTE, MD, Prof.
-
Marseille, France
- Recruiting
-
Paris, France
- Recruiting
-
Saint-louis, France
- Recruiting
-
-
-
-
-
Kiel, Germany
- Recruiting
-
Ratzeburg, Germany
- Recruiting
-
Würzburg, Germany
- Recruiting
-
-
-
-
-
Palermo, Italy
- Recruiting
-
Piacenza, Italy
- Recruiting
-
-
-
-
-
Fort-de-France, Martinique
- Recruiting
-
-
-
-
-
Yverdon-les-bains, Switzerland
- Recruiting
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Bone skeletal defects that are not intrinsic to the stability of bone structure OR site which can be stabilized
- Bone defects from surgery, trauma, tumor or cyst
- Age ≥ 18 years
- Patient information and signed informed consent form (for data collection)
- Affiliation to a Social Security System schema (or similar system)
Exclusion Criteria:
- Patients undergoing radiotherapy or chemotherapy
- Patients with inflammatory bone disease
- Patients with a calcium metabolism anomaly, severe metabolic disease, vascular or neurological diseases, or immunological deficiencies
- Bone site which can lead to the product passing into the joint cavities without appropriate controls (visual, arthroscopic, lavage…).
- Bone site which can lead to the product passing into the meningeal spaces
- Vertebroplasty and kyphoplasty
- Site infected or one suspected of being so
- A cranio-maxillofacial defect with a surface area larger than 25 cm2
- A site exposed to the sinus (lumen) or nasal mucosa
- Pregnant women (or likely to be) or breast-feeding women
- Inability to understand the consent and objectives of the study
- Unable to undergo medical monitoring for geographical, social or psychological reasons
- Persons who are deprived of liberty or under guardianship
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Device Effect rate
Time Frame: For 24 months
|
Rate of Adverse Events related to bone substitutes (registry devices) for the follow-up period of patients.
|
For 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success rate
Time Frame: At surgical procedure
|
Technical Success rate defined as successful delivery of the bone substitute in the target defect bone without evidence of delivery device or bone substitute malfunction.
(NOTE: Malfunction is definied as a failure of the medical device to perform in accordance with its intended purpose when used in accordance with the Instructions For Uses (IFU)).
|
At surgical procedure
|
Device Deficiencies rate
Time Frame: At surgical procedure
|
Device deficiency is defined as an inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance. NOTE: Device deficiencies include malfunctions, use errors, and inadequate labelling. |
At surgical procedure
|
Serious Adverse Events rate in the peroperative period
Time Frame: At surgical procedure
|
Serious Adverse Event is defined as any adverse event that:
|
At surgical procedure
|
Serious Adverse Events rate during the follow-up period
Time Frame: 3 months post index procedure
|
Serious Adverse Event is defined as any adverse event that:
|
3 months post index procedure
|
Serious Adverse Events rate during the follow-up period
Time Frame: 6 months post index procedure
|
Serious Adverse Event is defined as any adverse event that:
|
6 months post index procedure
|
Serious Adverse Events rate during the follow-up period
Time Frame: 9 months post index procedure
|
Serious Adverse Event is defined as any adverse event that:
|
9 months post index procedure
|
Serious Adverse Events rate during the follow-up period
Time Frame: 12 months post index procedure
|
Serious Adverse Event is defined as any adverse event that:
|
12 months post index procedure
|
Serious Adverse Events rate during the follow-up period
Time Frame: 24 months post index procedure
|
Serious Adverse Event is defined as any adverse event that:
|
24 months post index procedure
|
Bone reconstruction evolution after surgery (if X-rays are available)
Time Frame: 3 months post index procedure
|
X-ray scoring systems have been implemented according to the medical literature criteria.
For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria.
As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant.
The maximum score for both groups (trauma/arthrodesis & cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
|
3 months post index procedure
|
Bone reconstruction evolution after surgery (if X-rays are available)
Time Frame: 6 months post index procedure
|
X-ray scoring systems have been implemented according to the medical literature criteria.
For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria.
As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant.
The maximum score for both groups (trauma/arthrodesis & cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
|
6 months post index procedure
|
Bone reconstruction evolution after surgery (if X-rays are available)
Time Frame: 9 months post index procedure
|
X-ray scoring systems have been implemented according to the medical literature criteria.
For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria.
As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant.
The maximum score for both groups (trauma/arthrodesis & cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
|
9 months post index procedure
|
Bone reconstruction evolution after surgery (if X-rays are available)
Time Frame: 12 months post index procedure
|
X-ray scoring systems have been implemented according to the medical literature criteria.
For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria.
As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant.
The maximum score for both groups (trauma/arthrodesis & cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
|
12 months post index procedure
|
Bone reconstruction evolution after surgery (if X-rays are available)
Time Frame: 24 months post index procedure
|
X-ray scoring systems have been implemented according to the medical literature criteria.
For trauma defects/arthrodesis, the results are scored using the criteria proposed by Lane and Sandhu (bone formation, union and remodeling) and also including a bone substitute resorption (radiolucency) criteria.
As for prosthesis revision/cavity defects, the scoring system includes bone substitute resorption, bone formation, remodeling and presence or absence of a radiolucent line between the bone and the cement/implant.
The maximum score for both groups (trauma/arthrodesis & cavity filling/arthroplasty) is 10/10 (excellent consolidation/excellent secondary stabilization) and the minimum score is 0/10 (no consolidation/no secondary stabilization).
|
24 months post index procedure
|
Quality of life score at baseline (EQ-5D-3L)
Time Frame: At baseline (pre-operative)
|
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients.
EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview.
The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS.
The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).
Each dimension has 3 levels: no problems, some problems, extreme problems.
EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
|
At baseline (pre-operative)
|
Quality of life score evolution after surgery (EQ-5D-3L)
Time Frame: 3 months post index procedure
|
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients.
EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview.
The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS.
The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).
Each dimension has 3 levels: no problems, some problems, extreme problems.
EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
|
3 months post index procedure
|
Quality of life score evolution after surgery (EQ-5D-3L)
Time Frame: 6 months post index procedure
|
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients.
EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview.
The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS.
The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).
Each dimension has 3 levels: no problems, some problems, extreme problems.
EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
|
6 months post index procedure
|
Quality of life score evolution after surgery (EQ-5D-3L)
Time Frame: 9 months post index procedure
|
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients.
EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview.
The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS.
The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).
Each dimension has 3 levels: no problems, some problems, extreme problems.
EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
|
9 months post index procedure
|
Quality of life score evolution after surgery (EQ-5D-3L)
Time Frame: 12 months post index procedure
|
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients.
EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview.
The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS.
The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).
Each dimension has 3 levels: no problems, some problems, extreme problems.
EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
|
12 months post index procedure
|
Quality of life score evolution after surgery (EQ-5D-3L)
Time Frame: 24 months post index procedure
|
This health status information is collected before and after a procedure and provides an indication of the clinical outcomes or quality of care delivered to patients.
EQ-5D-3L paper questionnaire will be self-administered or it will be administered to patient via a telephone interview.
The EQ-5D-5L still consists of 2 parts - the EQ-5D-5L descriptive system and the EQ VAS.
The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).
Each dimension has 3 levels: no problems, some problems, extreme problems.
EQ VAS is a scale on which the "best imaginable health state" is marked 100 and the "worst imaginable state" is marked 0.
|
24 months post index procedure
|
Functional score at baseline (if applicable according to the type of bone defect/medical indication).
Time Frame: At baseline (pre-operative)
|
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
|
At baseline (pre-operative)
|
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time Frame: 3 months post index procedure
|
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
|
3 months post index procedure
|
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time Frame: 6 months post index procedure
|
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
|
6 months post index procedure
|
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time Frame: 9 months post index procedure
|
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
|
9 months post index procedure
|
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time Frame: 12 months post index procedure
|
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
|
12 months post index procedure
|
Functional score evolution after surgery (if applicable according to the type of bone defect/medical indication).
Time Frame: 24 months post index procedure
|
Functional scores are used to monitor the patient progress. The questionnaires concern the degree of difficulty (level of function) that the patient experienced in performing usual daily activities and higher level activities due to his bone defect. Therefore, the type of functional score depends on the skeletal region impacted by the bone defect:
|
24 months post index procedure
|
Surgeon's Satisfaction survey with registry device
Time Frame: At surgical procedure
|
Surgeon's Satisfaction survey with registry device (about mixing ability, injecting ability and moldability) thanks to a 100-mm Visual Analog Scale (VAS).
A score of zero indicated absolutely inacceptable, while a score of 100 indicated very satisfying.
|
At surgical procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sébastien PARRATTE, MD, Prof, Hospital of "LA TIMONE"
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GR-NI-INJ
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Disease
-
University of EdinburghEuropean Research CouncilRecruitingPaget Disease | Paget Disease of BoneUnited Kingdom
-
Cares, Kristen, M.D.RecruitingInflammatory Bone DiseaseUnited States
-
Leiden University Medical CenterMaasstad Hospital; Alrijne HospitalRecruitingIBD | Inflammatory Bone DiseaseNetherlands
-
AmgenWithdrawnSolid Tumor | Metastatic Bone Disease
-
Novartis PharmaceuticalsCompletedPaget's Disease of BoneUnited States, Germany, Spain, United Kingdom, Canada, France, Belgium, South Africa, Australia, New Zealand
-
Johns Hopkins UniversityActive, not recruiting
-
Organon and CoCompleted
-
The Hospital for Sick ChildrenRare Disease Foundation, Vancouver, CanadaCompleted
-
Novartis PharmaceuticalsCompletedPaget's Disease of BoneChina
-
Novartis PharmaceuticalsCompletedPaget's Disease of BoneUnited States, United Kingdom, Canada, New Zealand, Spain, Australia